Cypress Capital Group’s Idexx Laboratories IDXX Stock Holding History

Cypress Capital Group’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,044	Closed	-$340K	–	296
2022 Q3	$340K	Sell	1,044 -4	-0.4%	-$1.47K	0.06%	218
2022 Q2	$368K	Sell	1,048 -576	-35%	-$235K	0.06%	225
2022 Q1	$889K	Sell	1,624 -495	-23%	-$260K	0.11%	160
2021 Q4	$1.4M	Sell	2,119 -10	-0.5%	-$6.28K	0.17%	111
2021 Q3	$1.32M	Buy	2,129 +375	+21%	+$252K	0.18%	113
2021 Q2	$1.11M	Sell	1,754 -55	-3%	-$30.4K	0.15%	131
2021 Q1	$885K	Buy	1,809 +16	+0.9%	+$8.02K	0.13%	156
2020 Q4	$896K	Buy	1,793 +444	+33%	+$199K	0.13%	133
2020 Q3	$531K	Buy	+1,349	New	+$499K	0.09%	171

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cypress Capital Group's IDXX Position: Q4 2022 in Review

Cypress Capital Group sold out of Idexx Laboratories (IDXX) in Q4 2022, closing a stake of 1,044 shares — an estimated $340K sold.

Cypress Capital Group first reported a position in IDXX in Q3 2020 and held it in 9 quarters. The position peaked at $1.4M in Q4 2021. 999 funds tracked by Wall St. Rank hold IDXX as of Q4 2022.

Cypress Capital Group reported no remaining Idexx Laboratories position as of Q4 2022 after selling out during the quarter.
Cypress Capital Group sold 1,044 Idexx Laboratories shares in Q4 2022, an estimated $340K.
Cypress Capital Group first reported a position in Idexx Laboratories in Q3 2020 and held it in 9 quarters.
Cypress Capital Group's Idexx Laboratories position peaked at $1.4M in Q4 2021.
999 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2022.

Based on Cypress Capital Group's 13F filing for Q4 2022, filed 14 Feb 2023.